Leo Cancer Care Raises $65m to Expand Upright Radiotherapy Platform

The new funding will accelerate manufacturing and commercial deployment of the FDA-cleared Marie system, which reimagines proton therapy by rotating the patient instead of the treatment machine.

Leo Cancer Care has secured $65 million in Series D financing to expand manufacturing and commercial deployment of its Marie upright radiotherapy platform, following growing interest in the company's patient-centred approach to cancer treatment.

The oversubscribed funding round was led by Yu Galaxy and included participation from new investor Eventide Asset Management, alongside existing shareholders.

Funding to Accelerate Commercial Growth

The latest investment follows Leo Cancer Care's $40 million fundraising completed in September 2025.

According to the company, the new capital will be used to:

• Expand manufacturing capacity.

• Accelerate commercial deployment of the Marie platform.

• Support ongoing clinical research and product development.

• Advance its broader upright radiotherapy strategy across proton therapy, photon therapy and medical imaging.
  

Rethinking Radiotherapy Delivery

At the centre of Leo's technology is Marie, an integrated upright patient positioning system and CT scanner designed for proton therapy.

Unlike conventional radiotherapy systems, where a large gantry rotates around a patient lying flat, Marie keeps the treatment equipment fixed while rotating the patient into the required treatment position.

The company believes this upright approach can improve anatomical consistency and organ stability during treatment, potentially enhancing treatment precision while simplifying system design.

Building Momentum Following FDA Clearance

Marie received US Food and Drug Administration (FDA) 510(k) clearance in July 2025.

Since then, the platform has attracted growing interest from leading cancer centres.

In June, the system was used during the world's first compact upright proton therapy treatment at Stanford Medicine Cancer Center, demonstrating the clinical feasibility of the company's novel treatment approach.

The milestone marked an important step towards broader adoption of upright proton therapy in clinical practice.

Expanding Access to Advanced Cancer Care

Leo Cancer Care says its long-term strategy is to redesign radiotherapy around the patient rather than the treatment machine.

The company believes upright treatment systems could make advanced cancer therapies more accessible by reducing infrastructure requirements while maintaining treatment quality.

Alongside the financing announcement, Leo also revealed it is preparing to announce a strategic partnership with a major international healthcare company, with further details expected in the coming weeks.

Why the Funding Matters

The investment reflects several important trends across radiation oncology:

• Companies are exploring new treatment workflows that improve both patient experience and operational efficiency.

• Proton therapy continues to expand beyond specialist centres through more compact technologies.

• Innovation is increasingly focused on improving access to advanced radiotherapy rather than simply reducing equipment costs.

• Investors remain supportive of technologies that could reshape cancer treatment delivery.
  

Summary

Leo Cancer Care has raised $65 million to accelerate commercial rollout of its FDA-cleared Marie upright radiotherapy platform.

The funding will support manufacturing expansion, clinical development and broader deployment of a system designed to transform proton therapy by rotating the patient rather than the treatment machine, as interest in upright cancer treatment continues to grow.

---

Discover how nuaxia can support your next medical education initiative:

• Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector 

• Contact us on: support@nuaxia.com